These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4911189)

  • 1. Complementary arguments in favor of the betacytotrophic action of the hypglycemic sulfonamides.
    Loubatières AL
    Adv Metab Disord; 1970; 1():Suppl 1:411+. PubMed ID: 4911189
    [No Abstract]   [Full Text] [Related]  

  • 2. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A; Mariani MM; Ribes G; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
    [No Abstract]   [Full Text] [Related]  

  • 4. [The present status of the question of the mechanism of action of sulfanilamide hypoglycemic preparations and several aspects of their use in the treatment of diabetes mellitus].
    Mordkovskaia NM
    Probl Endokrinol (Mosk); 1971; 17(5):121-5. PubMed ID: 4337075
    [No Abstract]   [Full Text] [Related]  

  • 5. [A morphological study on the mechanism of insulin-release, using sulfonylurea, l-leucine, and alpha-ketocarboxylic acids].
    Yoshinaga T
    Nihon Naibunpi Gakkai Zasshi; 1968 Oct; 44(7):741-9. PubMed ID: 4180485
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

  • 7. [Insulin secretion in the clinical stages of diabetes (with glucose tolerance test abnormalities)].
    Vague P; Vague J
    Journ Annu Diabetol Hotel Dieu; 1972; 13(0):55-65. PubMed ID: 4605752
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experimental study on glibenclamide (HB 419), a new particularly active hypoglycaemic sulphonamide. II. Betacytotrophic action and stimulation of the neogenesis of the islets of Langerhans].
    Loubatières A; Mariani MM; Alric R; Ribes G; de Malbosc H; Houareau MH
    Diabetologia; 1969 Aug; 5(4):219-27. PubMed ID: 4902718
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
    Tatoń J; Koliński P
    Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacological studies of a new highly effective blood sugar decreasing sulfonamide, glibenclamide (HB 419)].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Alric R; Chapal J
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1354-63. PubMed ID: 4899083
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacology and pharmacodynamics of a hypoglycemic sulfonamide very active on insulin secretion and the neogenesis of beta cells of pancreatic Langerhans islets].
    Loubatières A; Mariani MM; Ribes G
    C R Acad Hebd Seances Acad Sci D; 1970 Oct; 271(16):1446-7. PubMed ID: 4991543
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of increasing concentrations of glucose on insulin secretion. Synergy between glucose and hypoglycemic sulfonamides].
    Loubatières A; Mariani MM; Chapal J
    C R Seances Soc Biol Fil; 1968; 162(8):1575-80. PubMed ID: 4238184
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes.
    Guldstrand M; Grill V; Björklund A; Lins PE; Adamson U
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):448-56. PubMed ID: 12522324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The discovery of hypoglycemic sulfonamides and particularly of their action mechanism].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():20-56. PubMed ID: 4906982
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A; Ribes G; Mariani MM; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recent pharmacologic aspects of sulfamides modifying insulin secretion (hypoglycemic and hyperglycemic sulfamides)].
    Loubatiéres A; Mariani MM
    Actual Physiol Pathol (Paris); 1973; 4():237-66. PubMed ID: 4219256
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulinotropic effect and possible mode of action of a new potent sulfonylurea (BS-4231).
    Brisson GR; Malaisse WJ
    Can J Physiol Pharmacol; 1971 Jun; 49(6):536-44. PubMed ID: 4932540
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse.
    Williams AJ; Beales PE; Krug J; Procaccini E; Signore A; Xu S; Gale EA; Pozzilli P
    Diabetologia; 1993 Jun; 36(6):487-92. PubMed ID: 8335169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current pathophysiological and clinical aspects of the mode of action of blood glucose lowering sulfonamides].
    Pfeiffer EF
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():477-502. PubMed ID: 4906024
    [No Abstract]   [Full Text] [Related]  

  • 20. Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells.
    Mariot P; Gilon P; Nenquin M; Henquin JC
    Diabetes; 1998 Mar; 47(3):365-73. PubMed ID: 9519741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.